Goldman Sachs reiterates a "Buy" rating for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), indicating confidence in the company's growth potential.The stock price of Madrigal Pharmaceuticals experienced a decrease of 3.26%, showing market volatility.Madrigal's presentation at the 44th Annual J.P. Morgan Healthcare Conference highlights its strategic direction and developments in the NASH space.Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapi ...

Altimmune (ALT) Q2 2025 Earnings Call August 12, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. A reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Adviser t ...